Identification of toxemia in patients with clostridium difficile infection

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Yu, Hua ^a   Chen, Kevin ^a   Wu, Jianguo ^a,m   Yang, Zhiyong ^a   Shi, Lianfa ^a   Barlow, Lydia L ^b   Aronoff, David M ^c,d   Garey, Kevin W ^e,f,g   Savidge, Tor C ^h,i   Von Rosenvinge, Erik C ^b,j   Kelly, Ciaran P ^k,l   Feng, Hanping ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HOUSTON   (United States)

^f CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ TEXAS CHILDREN S HOSPITAL   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

^m SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; NEUTRALIZING ANTIBODY; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; ENTEROTOXIN; IMMUNOGLOBULIN G; RAC1 PROTEIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ABDOMINAL PAIN; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; BLOOD ANALYSIS; BLOOD SAMPLING; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLON DIVERTICULOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; MIDDLE AGED; TOXEMIA; TRAFFIC ACCIDENT; YOUNG ADULT; ANIMAL; BIOASSAY; BLOOD; BLOOD STORAGE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CLINICAL TRIAL; COMPLICATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FALSE NEGATIVE RESULT; GLYCOSYLATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY; MULTIPLE TRAUMA; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PROTEIN PROCESSING; PROTEIN STABILITY; RISK FACTOR; VERO CELL LINE;

ANIMALIA; CLOSTRIDIUM DIFFICILE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BACTERIAL PROTEINS; BACTERIAL TOXINS; BIOLOGICAL ASSAY; BLOOD PRESERVATION; CERCOPITHECUS AETHIOPS; CLOSTRIDIUM DIFFICILE; DIVERTICULITIS, COLONIC; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FALSE NEGATIVE REACTIONS; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; MULTIPLE TRAUMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; RAC1 GTP-BINDING PROTEIN; RISK FACTORS; TOXEMIA; VERO CELLS; YOUNG ADULT;

EID: 84928811782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124235     Document Type: Article

References (42)

1. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med. 2008; 359: 1932-1940. doi: 10.1056/NEJMra0707500 PMID: 18971494
2. Qualman SJ, Petric M, Karmali MA, Smith CR, Hamilton SR. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am J Clin Pathol. 1990; 94: 410-416. PMID: 1699407
3. Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel). 2010; 2: 1848-1880. doi: 10.3390/toxins2071848 PMID: 22069662
4. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002; 235: 363-372. PMID: 11882758
5. Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2001; 80: 88-101. PMID: 11159385
6. Jafri SF, Marshall JB. Ascites associated with antibiotic-associated pseudomembranous colitis. South Med J. 1996; 89: 1014-1017. PMID: 8865801
7. Zwiener RJ, Belknap WM, Quan R. Severe pseudomembranous enterocolitis in a child: case report and literature review. Pediatr Infect Dis J. 1989; 8: 876-882. PMID: 2696928
8. Johnson S, Kent SA, O'Leary KJ, Merrigan MM, Sambol SP, Peterson LR, et al. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med. 2001; 135: 434-438. PMID: 11560456
9. Sakurai T, Hajiro K, Takakuwa H, Nishi A, Aihara M, Chiba T. Liver abscess caused by Clostridium difficile. Scand J Infect Dis. 2001; 33: 69-70. PMID: 11234983
10. Libby DB, Bearman G. Bacteremia due to Clostridium difficile-review of the literature. Int J Infect Dis. 2009; 13(5):e305-309. doi: 10.1016/j.ijid.2009.01.014 PMID: 19398213
11. Shaikh N, Kettern MA, Hanssens Y, Elshafie SS, Louon A. A rare and unsuspected complication of Clostridium difficile infection. Intensive Care Med. 2008; 34: 963-966. PMID: 18026931
12. Jacob SS, Sebastian JC, Hiorns D, Jacob S, Mukerjee PK. Clostridium difficile and acute respiratory distress syndrome. Heart Lung. 2004; 33: 265-268. PMID: 15252417
13. Dobson G, Hickey C, Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 2003; 29: 1030. PMID: 12734650
14. Cunney RJ, Magee C, McNamara E, Smyth EG, Walshe J. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant. 1998; 13: 2842-2846. PMID: 9829488
15. Davies NL, Compson JE, Mackenzie B, O'Dowd VL, Oxbrow AK, Heads JT, et al. A Mixture of Functionally Oligoclonal Humanized Monoclonal Antibodies That Neutralize Clostridium difficile TcdA and TcdB with High Levels of In Vitro Potency Shows In Vivo Protection in a Hamster Infection Model. Clin Vaccine Immunol. 2013; 20: 377-390. doi: 10.1128/CVI.00625-12 PMID: 23324518
16. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362: 197-205. doi: 10.1056/ NEJMoa0907635 PMID: 20089970
17. Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997; 41: 366-370. PMID: 9378393
18. Bartlett JG, Chang TW, Moon N, Onderdonk AB. Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia. Am J Vet Res. 1978; 39: 1525-1530. PMID: 697162
19. He X, Wang J, Steele J, Sun X, Nie W, Tzipori S, et al. An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods. 2009; 78: 97-100. doi: 10.1016/j.mimet. 2009.04.007 PMID: 19393695
20. Steele J, Chen K, Sun X, Zhang Y, Wang H, Tzipori S, et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis. 2012; 205: 384-391. doi: 10.1093/infdis/jir748 PMID: 22147798
21. Steele J, Feng H, Parry N, Tzipori S. Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis. 2010; 201: 428-434. doi: 10.1086/649799 PMID: 20039803
22. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31: 431-455. doi: 10.1086/651706 PMID: 20307191
23. Yang G, Zhou B, Wang J, He X, Sun X, Nie W, et al. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol. 2008; 8: 192. doi: 10.1186/1471-2180-8-192 PMID: 18990232
24. He X, Sun X, Wang J, Wang X, Zhang Q, Tzipori S, et al. Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun. 2009; 77:2294-2303. doi: 10.1128/IAI. 01577-08 PMID: 19307220
25. Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun. 2012; 80: 2678-2688. doi: 10.1128/IAI. 00215-12 PMID: 22615245
26. Brandes V, Schelle I, Brinkmann S, Schulz F, Schwarz J, Gerhard R, et al. Protection from Clostridium difficile toxin B-catalysed Rac1/Cdc42 glucosylation by tauroursodeoxycholic acid-induced Rac1/ Cdc42 phosphorylation. Biol Chem. 2012; 393: 77-84. doi: 10.1515/BC-2011-198 PMID: 22628301
27. Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun. 1995; 63: 4619-4627. PMID: 7591115
28. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1432-1442. doi: 10.1002/ibd.20500 PMID: 18484669
29. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008; 46 Suppl 1: S12-18. doi: 10.1086/521863 PMID: 18177217
30. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982; 46: 86-94. PMID: 6806598
31. Jafari NV, Allan E, Bajaj-Elliott M. Human intestinal epithelial response(s) to Clostridium difficile. Methods Mol Biol. 2010; 646: 135-146. doi: 10.1007/978-1-60327-365-7-9 PMID: 20597007
32. Mullan N, Hughes KR, Mahida YR. Primary human colonic myofibroblasts are resistant to Clostridium difficile toxin A-induced, but not toxin B-induced, cell death. Infect Immun. 2011; 79: 1623-1630. doi: 10.1128/IAI.00686-10 PMID: 21245273
33. Brito GA, Sullivan GW, Ciesla WP Jr, Carper HT, Mandell GL, Guerrant RL. Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function. J Infect Dis. 2002; 185: 1297-1306. PMID: 12001047
34. Solomon K, Webb J, Ali N, Robins RA, Mahida YR. Monocytes are highly sensitive to clostridium difficile toxin A-induced apoptotic and nonapoptotic cell death. Infect Immun. 2005; 73: 1625-1634. PMID: 15731062
35. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005; 18: 247-263. PMID: 15831824
36. Grossmann EM, Longo WE, Kaminski DL, Smith GS, Murphy CE, Durham RL, et al. Clostridium difficile toxin: cytoskeletal changes and lactate dehydrogenase release in hepatocytes. J Surg Res. 2000; 88: 165-172. PMID: 10644484
37. Mazuski JE, Grossmann EM, Norman JG, Denham W, Panesar N, Shapiro MJ, et al. Clostridium difficile toxins influence hepatocyte protein synthesis through the interleukin 1 receptor. Arch Surg. 2000; 135: 1206-1211. PMID: 11030883
38. Florin I. Isolation of a fibroblast mutant resistant to Clostridium difficile toxins A and B. Microb Pathog. 1991; 11: 337-346. PMID: 1816487
39. Clerk A, Pham FH, Fuller SJ, Sahai E, Aktories K, Marais R, et al. Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. Mol Cell Biol. 2001; 21: 1173-1184. PMID: 11158304
40. Hamm EE, Voth DE, Ballard JD. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A. 2006; 103: 14176-14181. PMID: 16966605
41. Kotloff KL, Wasserman SS, Losonsky GA, ThomasWJr, Nichols R, Edelman R, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001; 69: 988-995. PMID: 11159994
42. Owens RC. Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26: 299-311. PMID: 16503710